Floatz logo

CITALOPRAM

Bipolar Disorder

University of Texas Southwestern Medical CenterSmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
73/ 100

Competitive context

67 Active assets in the Bipolar Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Dr. Stavroula Rakitzi
Phase 4BBB
LAMOTRIGINE
Johns Hopkins University
Phase 4BBB
LITHIUM, ELEMENTAL
University of Aarhus
Phase 4BBB
Paroxetine
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Phase 4BBB
Cipralex
First Affiliated Hospital of Zhejiang University
Phase 4BBB

View all 50 →

Same molecule, other indications

CITALOPRAM is also rated in:

Bipolar I DisorderDormant
BBB
Indicative ·
77 / 100
View asset →
Psychotic DisordersDormant
BBB
Indicative ·
74 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →